Harnessing the power of CAR-T cell therapy
We develop both autologous and allogeneic approaches to improve outcomes in cancer treatment
At OneChain, we are building a diversified portfolio of CAR‑T cell candidates designed to tackle some of the most challenging forms of cancer. By combining innovative targeting strategies with adaptable cell platforms, our goal is to broaden the scope and reach of this promising technology, which offers high precision, long-lasting responses and the potential to overcome resistance in both haematological malignancies and solid tumours.
A robust pipeline built on innovation
CAR T cell candidates targeting high need blood cancers and solid tumours
Our pipeline includes five CAR‑T cell candidates developed to address unmet medical needs in both haematological malignancies and solid tumours — a field where CAR‑T therapies remain in early stages. With novel antigen combinations, dual‑targeting strategies and an allogeneic platform in development, we’re working to bring the benefits of cellular immunotherapy to broader patient populations.
